Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Medical Director, Liver Disease Management and Transplant Program
California Pacific Medical Center
San Francisco, California
Practicing Physician, Internal Medicine
San Francisco, California
| Credit Types: | CME |
| Credit Amount: | 0.5 Credits |
| Release Date: | 2010-Feb-02 |
| Estimated Time for Completion: | 30 minutes |
| Registration Required: | No |
| Cost: | Free |
In this activity, two experts in hepatitis B discuss screening and management of hepatitis B in the primary care setting.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of primary care physicians and other clinicians involved in diagnosing and managing patients with hepatitis B.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: February 02, 2010 - February 01, 2011
Time to Complete: 30 minutes
Robert G. Gish, MD
Medical Director, Liver Disease Management and Transplant Program
California Pacific Medical Center
San Francisco, California
Robert G. Gish, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Anadys Pharmaceuticals, Inc.; Bayer AG; Bristol-Myers Squibb Company; F. Hoffmann-LaRoche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; GlobeImmune, Inc.; Hepahope, Inc.; Human Genome Sciences, Inc.; Idenix Pharmaceuticals; Innogenetics, Inc.; Merck & Co., Inc.; Metabasis Therapeutics, Inc.; Nucleonics, Inc.; Pharmasset, Inc.; Schering-Plough Corporation; SciClone Pharmaceuticals, Inc.; Valeant Pharmaceuticals North America; and ZymoGenetics, Inc.
Grant/Research Support from Bristol-Myers Squibb Company; F. Hoffmann-LaRoche Ltd; Gilead Sciences, Inc.; GlobeImmune, Inc.; Idenix Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Nucleonics Inc.; Pfizer Inc; Schering-Plough Corporation; SciClone Pharmaceuticals, Inc.; and Valeant Pharmaceuticals North Amercia.
Speakers Bureau participant with Bristol-Myers Squibb Company; F. Hoffmann-LaRoche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Ortho Biotech Products, L.P.; Salix Pharmaceuticals, Inc.; Schering-Plough Corporation; and Three Rivers Pharmaceuticals.
Christopher C. Wong, MD
Practicing Physician, Internal Medicine
San Francisco, California
Christopher C. Wong, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb Company and Gilead Sciences, Inc.
Robert J. Fontana, MD
Associate Professor
Medical Director
Liver Transplantation
Division of Gastroenterology
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, Michigan
Robert J. Fontana, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Roche Laboratories Inc.
Mr. Pierre Lavalard, MBA
Associate Director
Office of CME
Department of Medical Education
University of Michigan Medical School
Ann Arbor, Michigan
Mr. Pierre Lavalard, MBA, currently has no financial interests/relationships or affiliations in relation to this activity.
Annette Wiggins
PVI, PeerView Institute for Medical Education, Inc.
Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
The University of Michigan Medical School designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from 
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Do you know which pts to screen for hepatitis B? Select one of the following.
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high quality CME content by adding the OpenCME Widget to one or more of your pages.